A new short paper of interest (to me) amongst all of the tweets.
Midkine, a middle manager of ß2 integrins
by M. Herter and Tanya N. Mayadas
the authors are getting to the heart of midkine's signalling / inflammation role which mobilises certain white blood cell cells (neutrophils)to the site of a trauma.
The authors conclude:
"In summary, Weckbach et al have provided
a molecular mechanism for the observed
requirement for MK in leukocyte extravasation
in many in?ammation models. The speci?c
function of MK for a discrete process in
leukocyte recruitment and its extracellular
accessibility make it an IDEAL TARGET FOR PHARMACOLOGIC INTERVENTION." [my capitalisations]
This is coming from Harvard Medical School and the authors declare not conflict of interest.
cheers
- Forums
- ASX - By Stock
- AN1
- pipeline update
pipeline update, page-26
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AN1 (ASX) to my watchlist
|
|||||
Last
0.7¢ |
Change
-0.001(12.5%) |
Mkt cap ! $3.229M |
Open | High | Low | Value | Volume |
0.7¢ | 0.7¢ | 0.7¢ | $69 | 9.915K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 577132 | 0.7¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.9¢ | 375029 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 577132 | 0.007 |
4 | 2016527 | 0.006 |
1 | 300000 | 0.005 |
2 | 525000 | 0.004 |
1 | 600000 | 0.003 |
Price($) | Vol. | No. |
---|---|---|
0.009 | 375029 | 2 |
0.010 | 157763 | 1 |
0.013 | 750000 | 1 |
0.015 | 340000 | 2 |
0.022 | 4000 | 1 |
Last trade - 09.59am 29/07/2024 (20 minute delay) ? |
Featured News
IGO
IGO kicks off earn-in copper drilling on-site Encounter's Yeneena play as it adopts new identity
NVA
Nova locks in NASDAQ US market listing at a value of only US$3.3M as ASX gets quieter and quieter
AN1 (ASX) Chart |